This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Diabetic Retinopathy  • Macular Disorders  • Alert me on articles by topic

Are Intravitreal Steroids a Possible Answer?

Arch Ophthalmol. 2005;123:259-261.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The recent emphasis on new pharmacologic treatments for exudative age-related macular degeneration and diabetic retinopathy, while commendable, has tended to obscure the fact that another common retinal disorder, central retinal vein occlusion, is, for the most part, untreatable with significant visual morbidity. Based on a recent population-based survey of retinal venous occlusive disease in adults¹ and US census figures for 2000,² as many as 36 500 persons per year develop central retinal vein occlusion in the United States alone. Coupled with as many as 95 000 persons per year who develop branch retinal vein occlusion, the 2 entities combined may account for significant vision loss in more than 130 000 persons per year in the United States. This begins to approach the annual incidence of cases of exudative age-related macular degeneration and makes it increasingly apparent from a public health standpoint that new and effective therapies are desperately needed.

The 1 large therapeutic . . . [Full Text of this Article]

AUTHOR INFORMATION
Mark S. Blumenkranz, MD

RELATED ARTICLE

Intravitreal Triamcinolone Acetonide for Macular Edema Associated With Diabetic Retinopathy and Venous Occlusive Disease: It’s Time for Clinical Trials
Harry W. Flynn, Jr and Ingrid U. Scott
Arch Ophthalmol. 2005;123(2):258-259.
EXTRACT | FULL TEXT